Telomir Pharmaceuticals, Inc. Common Stock
TELO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $121,702 | $207,269 | $207,269 | $207,269 |
| - Cash | $1,266 | $1 | $1 | $0 |
| + Debt | $93 | $101 | $582 | $119 |
| Enterprise Value | $120,529 | $207,368 | $207,849 | $207,388 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | $48 | -$11,429 | $0 | $0 |
| % Margin | – | – | – | – |
| Net Income | -$16,533 | -$13,072 | -$854 | -$138 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.56 | -0.44 | -0.029 | -0.005 |
| % Growth | -27.3% | -1,427.8% | -512.8% | – |
| Operating Cash Flow | -$5,070 | -$3,860 | -$469 | -$119 |
| Capital Expenditures | $0 | -$0 | $0 | -$0 |
| Free Cash Flow | -$5,070 | -$3,860 | -$469 | -$119 |